ITM

Highly Engaged Employees

ITM, founded in 2004, is a leading radiopharmaceutical biotech company focused on next-generation therapeutics and diagnostics for hard-to-treat tumors. It aims to meet critical needs for cancer patients, clinicians, and partners through excellence in development, production, and global supply of medical radioisotopes. Driven by improved patient benefit, ITM advances a precision oncology pipeline with multiple Phase 3 studies, combining high-quality radioisotopes with targeting molecules to revolutionize cancer treatment.

With two decades of radiopharma expertise, ITM operates with 500 - 1,000 employees across 1 location. Its strength lies in an established global network and central industry position, ensuring consistent supply of medical radioisotopes under GMP standards. This operational excellence supports ITM's strategy to improve clinical outcomes and patient quality of life. To learn more about the people behind these innovations, one can Meet ITM's team.

ITM reports a revenue of $230.6M and has secured significant funding, including substantial debt and private equity investments, reflecting strong investor confidence. These financial milestones fuel ongoing R&D and advanced pipeline studies. Explore financial highlights for detailed performance and investment history. ITM's specialized focus in pharmaceuticals and healthcare positions it for continued impact in targeted cancer therapies.